

Angiolo Gadducci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4504352/publications.pdf>

Version: 2024-02-01

225
papers

8,487
citations

30070

54
h-index

66911

78
g-index

227
all docs

227
docs citations

227
times ranked

7927
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach. <i>Tumori</i> , 2022, 108, 376-385.	1.1	8
2	Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex. <i>European Surgical Research</i> , 2022, 63, 114-122.	1.3	5
3	Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study. <i>Anticancer Research</i> , 2022, 42, 947-954.	1.1	3
4	Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. <i>Anticancer Research</i> , 2022, 42, 2017-2022.	1.1	8
5	Endometrial Cancer: When Upfront Surgery Is Not an Option. <i>Oncology</i> , 2021, 99, 65-71.	1.9	13
6	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	1.1	8
7	Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy. <i>In Vivo</i> , 2021, 35, 1051-1056.	1.3	4
8	The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer. <i>Anticancer Research</i> , 2021, 41, 9-20.	1.1	8
9	Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 537-544.	2.5	4
10	A narrative review of pregnancy after malignancies in young women that donâ€™t originate in the female genital organs or in the breast. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103240.	4.4	1
11	Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study. <i>Anticancer Research</i> , 2021, 41, 1937-1944.	1.1	2
12	Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. <i>Anticancer Research</i> , 2021, 41, 4673-4685.	1.1	8
13	Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. <i>Gynecologic Oncology</i> , 2021, 162, 741-750.	1.4	49
14	Primary Perivascular Epithelioid Cell Tumor (PEComa) of the Ovary: A Case Report and Review of the Literature. <i>Anticancer Research</i> , 2021, 41, 4483-4488.	1.1	0
15	Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response. <i>Anticancer Research</i> , 2021, 41, 497-502.	1.1	5
16	The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study. <i>Cancers</i> , 2021, 13, 5468.	3.7	1
17	Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue â€œDiagnosis and Management of Endometrial Cancerâ€. <i>Cancers</i> , 2021, 13, 6155.	3.7	5
18	Comparison between single-site and multiport robot-assisted hysterectomy in obese patients with endometrial cancer: An Italian multi-institutional study. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2020, 16, e2066.	2.3	7

#	ARTICLE	IF	CITATIONS
19	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana Ginecologica Oncologica). <i>Gynecologic Oncology Reports</i> , 2020, 33, 100603.	0.78	14
20	Perivascular epithelioid cell tumors (PEComa) of the female genital tract: A challenging question for gynaecologic oncologist and pathologist. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100603.	0.6	10
21	Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2020, 40, 4819-4828.	1.1	66
22	Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research. <i>Cancers</i> , 2020, 12, 2678.	3.7	8
23	Pregnancy-associated cancers: frequency and temporal trends in Italy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 241-244.	2.5	5
24	Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. <i>Anticancer Research</i> , 2020, 40, 2429-2438.	1.1	12
25	Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2020, 158, 208-217.	1.4	17
26	Adenoid Cystic Carcinoma of Bartholin's Gland: What Is the Best Approach?. <i>Oncology</i> , 2020, 98, 513-519.	1.9	14
27	Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research. <i>Cancers</i> , 2020, 12, 1336.	3.7	27
28	Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma?. <i>Anticancer Research</i> , 2020, 40, 3031-3037.	1.1	12
29	Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study. <i>Anticancer Research</i> , 2020, 40, 2191-2197.	1.1	6
30	Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. <i>Anticancer Research</i> , 2020, 40, 1543-1550.	1.1	1
31	Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. <i>Anticancer Research</i> , 2020, 40, 5995-6002.	1.1	5
32	Uterine smooth muscle tumors of unknown malignant potential: A challenging question. <i>Gynecologic Oncology</i> , 2019, 154, 631-637.	1.4	46
33	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019, 12, 9.	3.0	83
34	Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 92-98.	4.4	33
35	Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 103-114.	4.4	58
36	Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study. <i>Anticancer Research</i> , 2019, 39, 2513-2517.	1.1	14

#	ARTICLE	IF	CITATIONS
37	Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. <i>Gynecologic Oncology</i> , 2019, 153, 684-693.	1.4	46
38	Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy. <i>Oncology</i> , 2019, 96, 235-241.	1.9	5
39	Definitive radiotherapy for recurrent vulvar carcinoma after primary surgery: a two-institutional Italian experience. <i>Tumori</i> , 2019, 105, 225-230.	1.1	9
40	Angiosarcoma after adjuvant radiotherapy in high-risk squamous cell carcinoma of the vulva: a case report. <i>Przegląd Menopauzalny</i> , 2019, 18, 230-234.	1.3	3
41	Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1134-1140.	2.5	8
42	A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab. <i>BMC Urology</i> , 2019, 19, 128.	1.4	8
43	Melanoma of the lower genital tract: Prognostic factors and treatment modalities. <i>Gynecologic Oncology</i> , 2018, 150, 180-189.	1.4	57
44	Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. <i>Gynecologic Oncology</i> , 2018, 151, 449-452.	1.4	11
45	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix – An Italian Multicenter Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 3627-3634.	1.1	9
46	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15
47	Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 3669-3675.	1.1	13
48	Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 1695-1703.	1.1	6
49	Neuroendocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2017, 144, 637-646.	1.4	98
50	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 153-165.	4.4	37
51	Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 28-36.	2.5	31
52	Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes. <i>Oncology Research and Treatment</i> , 2017, 40, 697-701.	1.2	17
53	Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1863-1871.	2.5	44
54	Adjuvant Radiotherapy in High-Risk Squamous Cell Carcinoma of the Vulva: A Two-Institutional Italian Experience. <i>Oncology Research and Treatment</i> , 2017, 40, 778-783.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Post-traumatic Stress Disorder in patients with ovarian cancer. <i>International Review of Psychiatry</i> , 2017, 29, 403-408.	2.8	4
56	Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). <i>Gynecological Endocrinology</i> , 2017, 33, 39-42.	1.7	79
57	Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemoradiotherapy in Cervical Cancer: a Preliminary Analysis. <i>Anticancer Research</i> , 2017, 37, 1249-1256.	1.1	18
58	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2017, 37, 5955-5965.	1.1	45
59	Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 512-517.	0.9	20
60	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	4.6	30
61	Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 73-83.	4.4	71
62	Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 489-495.	0.7	12
63	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	2.5	11
64	Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study. <i>Anticancer Research</i> , 2016, 36, 387-91.	1.1	1
65	Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study. <i>Anticancer Research</i> , 2016, 36, 1885-9.	1.1	16
66	PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2016, 36, 2055-64.	1.1	16
67	Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. <i>Anticancer Research</i> , 2016, 36, 3477-82.	1.1	9
68	Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?. <i>Gynecologic Oncology</i> , 2015, 136, 230-234.	1.4	41
69	Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 211-224.	4.4	71
70	Unilateral adnexal agenesis and dermoid cyst: fertility implications. <i>Gynecological Endocrinology</i> , 2015, 31, 438-440.	1.7	1
71	Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 113-128.	4.4	28
72	Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia. <i>Gynecological Endocrinology</i> , 2015, 31, 673-678.	1.7	15

#	ARTICLE	IF	CITATIONS
73	Pharmacological treatment for uterine leiomyosarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 335-346.	1.8	12
74	Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. <i>Anticancer Research</i> , 2015, 35, 1099-104.	1.1	5
75	Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours. <i>Gynecological Endocrinology</i> , 2014, 30, 467-471.	1.7	20
76	Comparison of the initial surgical experience with robotic and laparoscopic myomectomy. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2014, 10, 208-212.	2.3	45
77	The Role of HE4 in Ovarian Cancer Follow-up: A Review. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1359-1365.	2.5	36
78	Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 891-898.	1.0	40
79	Adjuvant chemotherapy in stage II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients. <i>Gynecologic Oncology</i> , 2014, 133, 531-536.	1.4	34
80	Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. <i>Gynecological Endocrinology</i> , 2014, 30, 266-271.	1.7	37
81	Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage II endometrial cancer: An Italian multicenter retrospective study (CTF study). <i>Gynecologic Oncology</i> , 2014, 134, 29-35.	1.4	17
82	Is there a role for postoperative treatment in patients with stage IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. <i>Gynecologic Oncology</i> , 2014, 132, 611-617.	1.4	68
83	Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9). <i>Oncology</i> , 2014, 86, 351-358.	1.9	20
84	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 72.	3.0	12
85	Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. <i>Gynecological Endocrinology</i> , 2014, 30, 612-617.	1.7	47
86	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5613-TPS5613.	1.6	3
87	Pathological response on surgical samples is an independent prognostic variable for patients with Stage IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study). <i>Gynecologic Oncology</i> , 2013, 131, 640-644.	1.4	58
88	Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. <i>Gynecological Endocrinology</i> , 2013, 29, 811-816.	1.7	10
89	Fertility outcome of breast cancer and Hodgkin's lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists. <i>Gynecological Endocrinology</i> , 2013, 29, 729-734.	1.7	2
90	Fertility drug use and risk of ovarian tumors: a debated clinical challenge. <i>Gynecological Endocrinology</i> , 2013, 29, 30-35.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Tissue biomarkers as prognostic variables of cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 104-129.	4.4	80
92	Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. <i>Gynecological Endocrinology</i> , 2013, 29, 25-29.	1.7	17
93	Alternatives to risk-reducing surgery for ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii47-viii53.	1.2	15
94	“Batâ€™ choroid plexus and other sonographic features in trisomy 22 at the first trimester of pregnancy. <i>Prenatal Diagnosis</i> , 2013, 33, 1013-1014.	2.3	2
95	Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. <i>British Journal of Cancer</i> , 2013, 109, 29-34.	6.4	113
96	Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 461-468.	2.5	19
97	New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. <i>Gynecological Endocrinology</i> , 2012, 28, 582-586.	1.7	12
98	Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1355-1360.	2.5	12
99	An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 792-800.	2.5	20
100	Could Different Follow-Up Modalities Play a Role in the Diagnosis of Asymptomatic Endometrial Cancer Relapses?: An Italian Multicentric Retrospective Analysis. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1013-1019.	2.5	32
101	Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 71-83.	4.4	54
102	Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. <i>Gynecologic Oncology</i> , 2012, 125, 673-676.	1.4	71
103	Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer. <i>Anticancer Research</i> , 2012, 32, 201-5.	1.1	7
104	Multimodality approach in extra cervical locally advanced cervical cancer: Chemoradiation, surgery and intra-operative radiation therapy. A phase II trial. <i>European Journal of Surgical Oncology</i> , 2011, 37, 442-447.	1.0	22
105	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	2.5	43
106	Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 181-192.	4.4	18
107	Prognostic factors in uterine sarcoma. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 783-795.	2.8	43
108	Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. <i>Gynecological Endocrinology</i> , 2011, 27, 597-604.	1.7	124

#	ARTICLE	IF	CITATIONS
109	The evolving role of adjuvant therapy in endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 79-91.	4.4	14
110	Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1414-1421.	2.5	84
111	Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. <i>Anticancer Research</i> , 2011, 31, 3483-8.	1.1	24
112	Surveillance Procedures for Patients Treated for Endometrial Cancer: A Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 985-992.	2.5	55
113	The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2010, 116, 358-363.	1.4	36
114	Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). <i>Gynecologic Oncology</i> , 2010, 119, 48-52.	1.4	78
115	The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 126-140.	4.4	29
116	Treatment options in recurrent cervical cancer (Review). <i>Oncology Letters</i> , 2010, 1, 3-11.	1.8	91
117	Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. <i>Gynecological Endocrinology</i> , 2010, 26, 568-577.	1.7	31
118	Pretreatment platelet and hemoglobin levels are neither predictive nor prognostic variables for patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: a retrospective Italian study. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1399-404.	2.5	22
119	Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. <i>Anticancer Research</i> , 2010, 30, 201-8.	1.1	14
120	Clear cell carcinoma of the endometrium: a biological and clinical enigma. <i>Anticancer Research</i> , 2010, 30, 1327-34.	1.1	41
121	Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. <i>Anticancer Research</i> , 2010, 30, 3731-5.	1.1	6
122	Surveillance Procedures for Patients With Cervical Carcinoma: A Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 194-201.	2.5	29
123	Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1. <i>Journal of Clinical Oncology</i> , 2009, 27, 4642-4648.	1.6	113
124	Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 12-27.	4.4	72
125	Surveillance of patients after initial treatment of ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 43-52.	4.4	67
126	Weekly epirubicin in the treatment of gestational breast cancer (GBC). <i>Breast Cancer Research and Treatment</i> , 2009, 115, 591-594.	2.5	68

#	ARTICLE	IF	CITATIONS
127	The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option. <i>Gynecological Endocrinology</i> , 2009, 25, 683-691.	1.7	44
128	Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue. <i>Gynecological Endocrinology</i> , 2009, 25, 807-815.	1.7	22
129	Dose Individualization Can Minimize Nephrotoxicity due to Carboplatin Therapy in Patients With Ovarian Cancer. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 63-69.	2.0	4
130	Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 615-619.	2.5	14
131	Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 367-374.	2.5	72
132	Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. <i>Anticancer Research</i> , 2009, 29, 1715-20.	1.1	49
133	The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 10-20.	4.4	131
134	The management of patients with uterine sarcoma: A debated clinical challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 129-142.	4.4	223
135	Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 90-94.	2.5	47
136	Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 615-620.	2.5	61
137	Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 943-953.	2.5	25
138	Molecular target therapies in endometrial cancer: From the basic research to the clinic. <i>Gynecological Endocrinology</i> , 2008, 24, 239-249.	1.7	42
139	Extra-Nuclear Signaling of Progesterone Receptor to Breast Cancer Cell Movement and Invasion through the Actin Cytoskeleton. <i>PLoS ONE</i> , 2008, 3, e2790.	2.5	75
140	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 225-238.	2.4	1
141	Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. <i>Cancer</i> , 2007, 109, 645-649.	4.1	28
142	Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). <i>International Journal of Gynecological Cancer</i> , 2007, 17, 623-628.	2.5	78
143	Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 21-31.	2.5	108
144	Follow-up strategies in gynecological oncology: searching appropriateness. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1186-1193.	2.5	16

#	ARTICLE	IF	CITATIONS
145	Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis?. <i>Gynecologic Oncology</i> , 2007, 107, S150-S154.	1.4	56
146	Biochemical prognostic factors and risk of relapses in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, S23-S26.	1.4	33
147	Ovarian function and childbearing issues in breast cancer survivors. <i>Gynecological Endocrinology</i> , 2007, 23, 625-631.	1.7	56
148	Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. <i>Anticancer Research</i> , 2007, 27, 4403-9.	1.1	17
149	Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 242-256.	4.4	70
150	Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 227-241.	4.4	99
151	Management of borderline ovarian tumors: Results of an Italian multicenter study. <i>Gynecologic Oncology</i> , 2006, 101, 255-260.	1.4	117
152	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 512-517.	1.4	124
153	Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer. <i>Women's Health</i> , 2006, 2, 141-158.	1.5	4
154	P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. <i>Anticancer Research</i> , 2006, 26, 687-93.	1.1	30
155	Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. <i>Anticancer Research</i> , 2006, 26, 3925-32.	1.1	15
156	Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 153-166.	4.4	53
157	Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2005, 98, 118-123.	1.4	7
158	Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 751-758.	1.6	46
159	Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. <i>Gynecological Endocrinology</i> , 2005, 20, 343-360.	1.7	38
160	Polycystic ovary syndrome and gynecological cancers: Is there a link?. <i>Gynecological Endocrinology</i> , 2005, 20, 200-208.	1.7	85
161	Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. <i>Anticancer Research</i> , 2005, 25, 2509-13.	1.1	14
162	Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. <i>Gynecological Endocrinology</i> , 2004, 19, 216-228.	1.7	19

#	ARTICLE	IF	CITATIONS
163	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 131-136.	1.4	49
164	Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. <i>Gynecologic Oncology</i> , 2004, 93, 345-352.	1.4	67
165	Serum tumor markers in the management of ovarian, endometrial and cervical cancer. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 24-38.	5.6	158
166	Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1031-44.	2.3	12
167	Is reduction in size pathognomonic of functional ovarian cysts?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2003, 21, 622-624.	1.7	0
168	First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2003, 89, 354-359.	1.4	20
169	The role of the French-Italian glossary of complications in the outcome evaluation of cervical cancer treatment: an Italian multicentric study. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 317-321.	4.4	2
170	Renal impairment in patients with ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 106, 198-202.	1.1	10
171	Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1320-1325.	1.6	26
172	Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. <i>Annals of Oncology</i> , 2003, 14, 1086-1093.	1.2	85
173	Intratatumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. <i>Anticancer Research</i> , 2003, 23, 549-56.	1.1	24
174	The management of malignant nondysgerminomatous ovarian germ cell tumors. <i>Anticancer Research</i> , 2003, 23, 1827-36.	1.1	4
175	Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. <i>Anticancer Research</i> , 2003, 23, 3001-8.	1.1	23
176	Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. <i>Anticancer Research</i> , 2003, 23, 5225-9.	1.1	72
177	Current management of fallopian tube carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 2002, 14, 27-32.	2.0	22
178	Analysis of the Evolution in the Management of Endometrial Cancer in Italy: A CTF Study. <i>Tumori</i> , 2002, 88, 481-488.	1.1	3
179	Gynecological Malignancies in Elderly Patients: Is Age 70 a Limit to Standard-Dose Chemotherapy? An Italian Retrospective Toxicity Multicentric Study. <i>Gynecologic Oncology</i> , 2002, 85, 445-450.	1.4	44
180	Controversial issues in climacteric medicine II. <i>Maturitas</i> , 2001, 40, 117-130.	2.4	29

#	ARTICLE	IF	CITATIONS
181	The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 277-282.	2.5	35
182	Second-line treatment and consolidation therapies in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 52-56.	2.5	21
183	Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 27-34.	4.4	17
184	Analysis of Treatment Failures and Survival of Patients with Fallopian Tube Carcinoma: A Cooperation Task Force (CTF) Study. <i>Gynecologic Oncology</i> , 2001, 81, 150-159.	1.4	93
185	Patterns of recurrence in patients with squamous cell carcinoma of the vulva. <i>Cancer</i> , 2000, 89, 116-122.	4.1	215
186	Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest. <i>Gynecologic Oncology</i> , 2000, 76, 157-162.	1.4	124
187	Complete Salvage Surgical Cytoreduction Improves Further Survival of Patients with Late Recurrent Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 79, 344-349.	1.4	118
188	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 145-152.	1.2	8
189	Up date in the management of advanced ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 49-58.	4.4	29
190	Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 76-81.	1.4	45
191	Analysis of Failures after Negative Second-Look in Patients with Advanced Ovarian Cancer: An Italian Multicenter Study. <i>Gynecologic Oncology</i> , 1998, 68, 150-155.	1.4	81
192	An Analysis of Approaches to the Management of Endometrial Cancer in North America: A CTF Study. <i>Gynecologic Oncology</i> , 1998, 68, 274-279.	1.4	83
193	Serum Macrophage Colony-Stimulating Factor (M-CSF) Levels in Patients with Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 70, 111-114.	1.4	20
194	Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1194-1200.	3.6	84
195	Survival after intestinal obstruction in patients with fatal ovarian cancer: Analysis of prognostic variables. <i>International Journal of Gynecological Cancer</i> , 1998, 8, 177-182.	2.5	15
196	Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1194-1200.	3.6	67
197	Intraperitoneal Carboplatin with or without Interferon- γ in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients. <i>Gynecologic Oncology</i> , 1997, 65, 499-505.	1.4	30
198	Preoperative D-Dimer Plasma Assay Is Not a Predictor of Clinical Outcome for Patients with Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 66, 85-88.	1.4	16

#	ARTICLE	IF	CITATIONS
199	Carcinosarcoma of the Uterus: A Clinicopathological Multicenter CTF Study. <i>Gynecologic Oncology</i> , 1997, 67, 70-75.	1.4	126
200	Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 78-83.	2.5	15
201	Ovarian cancer in elderly women. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 23-26.	2.5	1
202	Preoperative Evaluation of D-Dimer and CA 125 Levels in Differentiating Benign from Malignant Ovarian Masses. <i>Gynecologic Oncology</i> , 1996, 60, 197-202.	1.4	51
203	Differential Diagnosis of Adnexal Masses with Transvaginal Sonography, Color Flow Imaging, and Serum CA 125 Assay in Pre- and Postmenopausal Women. <i>Gynecologic Oncology</i> , 1996, 61, 68-72.	1.4	50
204	Prothrombin Fragment F1+2 and Thrombin Antithrombin III Complex (TAT) Plasma Levels in Patients with Gynecological Cancer. <i>Gynecologic Oncology</i> , 1996, 61, 215-217.	1.4	14
205	Uterine Leiomyosarcoma: Analysis of Treatment Failures and Survival. <i>Gynecologic Oncology</i> , 1996, 62, 25-32.	1.4	210
206	The Relationship between Postoperative Decline of Serum CA 125 Levels and Size of Residual Disease after Initial Surgery in Patients with Advanced Ovarian Cancer: A CTF Study. <i>Gynecologic Oncology</i> , 1996, 63, 234-237.	1.4	14
207	Endometrial Stromal Sarcoma: Analysis of Treatment Failures and Survival. <i>Gynecologic Oncology</i> , 1996, 63, 247-253.	1.4	183
208	Prevention of Cis-Platinum Nephrotoxicity in a High-Risk Patient. <i>Renal Failure</i> , 1996, 18, 691-695.	2.1	1
209	Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 175, 1606-1610.	1.3	11
210	Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1996, 6, 286-290.	2.5	12
211	An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study. <i>European Journal of Cancer</i> , 1995, 31, 1993-1997.	2.8	54
212	Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian Study. <i>Gynecologic Oncology</i> , 1995, 58, 42-47.	1.4	80
213	Serum Levels of Tumor Necrosis Factor (TNF), Soluble Receptors for TNF (55- and 75-kDa sTNFr), and Soluble CD14 (sCD14) in Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 58, 184-188.	1.4	41
214	The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl). <i>European Journal of Cancer</i> , 1994, 30, 1903-1904.	2.8	11
215	Elevated Serum Levels of Neopterin and Soluble Interleukin-2 Receptor in Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1994, 52, 386-391.	1.4	17
216	Pretreatment Plasma Levels of Fibrinogen (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 1994, 53, 352-356.	1.4	54

#	ARTICLE	IF	CITATIONS
217	Combined Use of CA 125 and CA 15-3 in Patients with Endometrial Carcinoma. <i>Gynecologic Oncology</i> , 1994, 54, 292-297.	1.4	58
218	Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 1432-1435.	2.8	29
219	Pretreatment Plasma Levels of Fibrinopeptide-A (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Operable Cervical Cancer: Influence of Surgical-Pathological Stage, Tumor Size, Histologic Type, and Lymph Node Status. <i>Gynecologic Oncology</i> , 1993, 49, 354-358.	1.4	42
220	Serum Soluble Interleukin-2 Receptor Assay in Epithelial Ovarian Cancer. <i>Tumor Biology</i> , 1993, 14, 303-309.	1.8	9
221	Combined Evaluation of Serum CA 125 and CAM 29 in Patients with Epithelial Ovarian Cancer. <i>Tumor Biology</i> , 1992, 13, 287-293.	1.8	1
222	The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis. <i>Gynecologic Oncology</i> , 1992, 44, 147-154.	1.4	110
223	The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients. <i>Gynecologic Oncology</i> , 1992, 44, 155-160.	1.4	45
224	Comparison of Tumor-Associated Trypsin Inhibitor (Tati) with Ca125 as a Marker for Diagnosis and Monitoring of Epithelial Ovarian Cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1991, 51, 19-24.	1.2	8
225	Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. <i>Gynecologic Oncology</i> , 1987, 28, 278-283.	1.4	15